Natera, Inc. balance sheet
At the end of fiscal 2025, Natera, Inc. had total assets of $2.40bn, total liabilities of $686m and shareholders' equity of $1.71bn. It held $1.08bn in cash against $80.3m of debt: net cash of $996m.
Balance sheet
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30 | 87 | 29 | 15 | 13 | 46 | 62 | 49 | 84 | 466 | 642 | 946 | 1,076 | 1,092 |
| Receivables | — | 6 | 6 | 13 | 44 | 62 | 53 | 79 | 122 | 244 | 278 | 314 | 297 | 422 |
| Inventory | — | 12 | 8 | 6 | 9 | 14 | 12 | 20 | 27 | 35 | 41 | 45 | 68 | 80 |
| Total current assets | — | 106 | 251 | 174 | 181 | 241 | 523 | 863 | 1,093 | 1,212 | 1,259 | 1,376 | 1,497 | 1,659 |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 141 | 141 |
| Total assets | — | 124 | 265 | 211 | 215 | 268 | 583 | 932 | 1,236 | 1,394 | 1,442 | 1,661 | 2,398 | 2,657 |
| Accounts payable | — | 9 | 7 | 11 | 9 | 15 | 9 | 8 | 27 | 31 | 15 | 35 | 33 | 75 |
| Deferred revenue (current) | — | 0 | 0 | 1 | 1 | 4 | 56 | 50 | 7 | 11 | 17 | 20 | 25 | 41 |
| Total current liabilities | — | 30 | 80 | 96 | 106 | 114 | 180 | 199 | 219 | 310 | 307 | 344 | 441 | 553 |
| Short-term debt | — | — | 42 | 50 | 50 | 50 | 50 | 50 | 50 | 80 | 80 | 80 | 80 | 80 |
| Long-term debt | — | — | — | — | — | — | — | — | 280 | 282 | 283 | — | — | — |
| Total debt | 0 | 4 | 67 | 50 | 50 | 50 | 75 | 75 | 330 | 362 | 363 | 80 | 80 | 80 |
| Total liabilities | — | 54 | 80 | 104 | 189 | 236 | 304 | 446 | 583 | 689 | 676 | 465 | 686 | 836 |
| Shareholders' equity | −172 | −171 | 226 | 144 | 25 | 32 | 279 | 486 | 653 | 706 | 765 | 1,195 | 1,712 | 1,821 |
| Non-controlling interests and other (assets − liabilities − equity) | — | 241 | −42 | −37 | — | — | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −30 | −84 | 38 | 34 | 37 | 4 | 13 | 26 | 246 | −104 | −279 | −865 | −996 | −1,011 |
| Shares outstanding | — | — | 50m | 53m | 54m | 62m | 78m | 86m | 95m | 111m | 120m | 133m | 140m | 144m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 307 | 314 | 318 | 309 | 286 | 297 | 418 | 422 |
| Inventory | 49 | 45 | 50 | 54 | 65 | 68 | 71 | 80 |
| Total current assets | 1,323 | 1,376 | 1,416 | 1,432 | 1,447 | 1,497 | 1,652 | 1,659 |
| Goodwill | — | — | — | — | — | 141 | 141 | 141 |
| Total assets | 1,591 | 1,661 | 1,732 | 1,757 | 1,821 | 2,398 | 2,614 | 2,657 |
| Accounts payable | 28 | 35 | 39 | 37 | 46 | 33 | 62 | 75 |
| Deferred revenue (current) | 18 | 20 | 21 | 22 | 22 | 25 | 37 | 41 |
| Total current liabilities | 301 | 344 | 366 | 385 | 442 | 441 | 558 | 553 |
| Short-term debt | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 |
| Total debt | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 |
| Total liabilities | 712 | 465 | 493 | 511 | 569 | 686 | 840 | 836 |
| Shareholders' equity | 879 | 1,195 | 1,240 | 1,246 | 1,252 | 1,712 | 1,774 | 1,821 |
| Shares outstanding | 124m | 133m | 136m | 137m | 138m | 140m | 143m | 144m |
Compare with peers
- Exelixis, Inc. balance sheet
- United Therapeutics Corp balance sheet
- Biontech SE balance sheet
- Moderna balance sheet
- Biomarin Pharmaceutical Inc balance sheet
Head to head: EXEL vs NTRANTRA vs UTHRBNTX vs NTRAMRNA vs NTRA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies